EANO guidelines for the diagnosis and treatment of meningiomas

Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D. Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen, Elizabeth Cohen Jonathan Moyal, Dieta Brandsma, Roger Henriksson, Riccardo Soffietti, Michael Weller

Research output: Contribution to journalReview article

119 Citations (Scopus)

Abstract

Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours such as high-grade gliomas. The meningioma task force of the European Association of Neuro-Oncology (EANO) assessed the scientific literature and composed a framework of the best possible evidence-based recommendations for health professionals. The provisional diagnosis of meningioma is mainly made by MRI. Definitive diagnosis, including histological classification, grading, and molecular profiling, requires a surgical procedure to obtain tumour tissue. Therefore, in many elderly patients, observation is the best therapeutic option. If therapy is deemed necessary, the standard treatment is gross total surgical resection including the involved dura. As an alternative, radiosurgery can be done for small tumours, or fractionated radiotherapy in large or previously treated tumours. Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable treatment of the complete tumour volume with low morbidity, are being developed. Pharmacotherapy for meningiomas has remained largely experimental. However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising candidates for future pharmacological approaches to treat refractory meningiomas across all WHO grades.

Original languageEnglish
Pages (from-to)e383-e391
JournalThe Lancet Oncology
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Meningioma
Guidelines
Radiosurgery
Neoplasms
Therapeutics
Radiotherapy
Literature
Drug Receptors
Peptide Receptors
Advisory Committees
Tumor Burden
Glioma
Radioisotopes
Observation
Pharmacology
Morbidity
Drug Therapy
Health

ASJC Scopus subject areas

  • Oncology

Cite this

Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., ... Weller, M. (2016). EANO guidelines for the diagnosis and treatment of meningiomas. The Lancet Oncology, 17(9), e383-e391. https://doi.org/10.1016/S1470-2045(16)30321-7

EANO guidelines for the diagnosis and treatment of meningiomas. / Goldbrunner, Roland; Minniti, Giuseppe; Preusser, Matthias; Jenkinson, Michael D.; Sallabanda, Kita; Houdart, Emmanuel; von Deimling, Andreas; Stavrinou, Pantelis; Lefranc, Florence; Lund-Johansen, Morten; Moyal, Elizabeth Cohen Jonathan; Brandsma, Dieta; Henriksson, Roger; Soffietti, Riccardo; Weller, Michael.

In: The Lancet Oncology, Vol. 17, No. 9, 01.09.2016, p. e383-e391.

Research output: Contribution to journalReview article

Goldbrunner, R, Minniti, G, Preusser, M, Jenkinson, MD, Sallabanda, K, Houdart, E, von Deimling, A, Stavrinou, P, Lefranc, F, Lund-Johansen, M, Moyal, ECJ, Brandsma, D, Henriksson, R, Soffietti, R & Weller, M 2016, 'EANO guidelines for the diagnosis and treatment of meningiomas', The Lancet Oncology, vol. 17, no. 9, pp. e383-e391. https://doi.org/10.1016/S1470-2045(16)30321-7
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E et al. EANO guidelines for the diagnosis and treatment of meningiomas. The Lancet Oncology. 2016 Sep 1;17(9):e383-e391. https://doi.org/10.1016/S1470-2045(16)30321-7
Goldbrunner, Roland ; Minniti, Giuseppe ; Preusser, Matthias ; Jenkinson, Michael D. ; Sallabanda, Kita ; Houdart, Emmanuel ; von Deimling, Andreas ; Stavrinou, Pantelis ; Lefranc, Florence ; Lund-Johansen, Morten ; Moyal, Elizabeth Cohen Jonathan ; Brandsma, Dieta ; Henriksson, Roger ; Soffietti, Riccardo ; Weller, Michael. / EANO guidelines for the diagnosis and treatment of meningiomas. In: The Lancet Oncology. 2016 ; Vol. 17, No. 9. pp. e383-e391.
@article{29a357e04b1d4296a9e475b3108a58c1,
title = "EANO guidelines for the diagnosis and treatment of meningiomas",
abstract = "Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours such as high-grade gliomas. The meningioma task force of the European Association of Neuro-Oncology (EANO) assessed the scientific literature and composed a framework of the best possible evidence-based recommendations for health professionals. The provisional diagnosis of meningioma is mainly made by MRI. Definitive diagnosis, including histological classification, grading, and molecular profiling, requires a surgical procedure to obtain tumour tissue. Therefore, in many elderly patients, observation is the best therapeutic option. If therapy is deemed necessary, the standard treatment is gross total surgical resection including the involved dura. As an alternative, radiosurgery can be done for small tumours, or fractionated radiotherapy in large or previously treated tumours. Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable treatment of the complete tumour volume with low morbidity, are being developed. Pharmacotherapy for meningiomas has remained largely experimental. However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising candidates for future pharmacological approaches to treat refractory meningiomas across all WHO grades.",
author = "Roland Goldbrunner and Giuseppe Minniti and Matthias Preusser and Jenkinson, {Michael D.} and Kita Sallabanda and Emmanuel Houdart and {von Deimling}, Andreas and Pantelis Stavrinou and Florence Lefranc and Morten Lund-Johansen and Moyal, {Elizabeth Cohen Jonathan} and Dieta Brandsma and Roger Henriksson and Riccardo Soffietti and Michael Weller",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/S1470-2045(16)30321-7",
language = "English",
volume = "17",
pages = "e383--e391",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - EANO guidelines for the diagnosis and treatment of meningiomas

AU - Goldbrunner, Roland

AU - Minniti, Giuseppe

AU - Preusser, Matthias

AU - Jenkinson, Michael D.

AU - Sallabanda, Kita

AU - Houdart, Emmanuel

AU - von Deimling, Andreas

AU - Stavrinou, Pantelis

AU - Lefranc, Florence

AU - Lund-Johansen, Morten

AU - Moyal, Elizabeth Cohen Jonathan

AU - Brandsma, Dieta

AU - Henriksson, Roger

AU - Soffietti, Riccardo

AU - Weller, Michael

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours such as high-grade gliomas. The meningioma task force of the European Association of Neuro-Oncology (EANO) assessed the scientific literature and composed a framework of the best possible evidence-based recommendations for health professionals. The provisional diagnosis of meningioma is mainly made by MRI. Definitive diagnosis, including histological classification, grading, and molecular profiling, requires a surgical procedure to obtain tumour tissue. Therefore, in many elderly patients, observation is the best therapeutic option. If therapy is deemed necessary, the standard treatment is gross total surgical resection including the involved dura. As an alternative, radiosurgery can be done for small tumours, or fractionated radiotherapy in large or previously treated tumours. Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable treatment of the complete tumour volume with low morbidity, are being developed. Pharmacotherapy for meningiomas has remained largely experimental. However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising candidates for future pharmacological approaches to treat refractory meningiomas across all WHO grades.

AB - Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours such as high-grade gliomas. The meningioma task force of the European Association of Neuro-Oncology (EANO) assessed the scientific literature and composed a framework of the best possible evidence-based recommendations for health professionals. The provisional diagnosis of meningioma is mainly made by MRI. Definitive diagnosis, including histological classification, grading, and molecular profiling, requires a surgical procedure to obtain tumour tissue. Therefore, in many elderly patients, observation is the best therapeutic option. If therapy is deemed necessary, the standard treatment is gross total surgical resection including the involved dura. As an alternative, radiosurgery can be done for small tumours, or fractionated radiotherapy in large or previously treated tumours. Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable treatment of the complete tumour volume with low morbidity, are being developed. Pharmacotherapy for meningiomas has remained largely experimental. However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising candidates for future pharmacological approaches to treat refractory meningiomas across all WHO grades.

UR - http://www.scopus.com/inward/record.url?scp=84994501911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994501911&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30321-7

DO - 10.1016/S1470-2045(16)30321-7

M3 - Review article

AN - SCOPUS:84994501911

VL - 17

SP - e383-e391

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 9

ER -